Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Carlsmed Inc
CARL
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$17.35
0.23
1.34%
In chiusura: Nov 13, 4:00 PM EST
$17.35
0.23
1.34%
Pre-mercato: 7:00 AM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data mar nov 10th, dopo la chiusura del mercato
Conference call:
La conference call più recente è iniziata alle 4:30 PM, 7 giorni fa
Clicca per vedere il webcast
Carlsmed Financials
Carlsmed (CARL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results
Carlsmed beats Q3 estimates, raises FY2026 sales guidance to $78M-$80M, and shares jump 19.5% as analysts lift price targets.
Avi Kapoor
PRO
UPDATE: Carlsmed Q3 Adj. EPS $(0.34) Beats $(0.40) Estimate, Sales $21.554M Beat $19.154M Estimate
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 15 percent increase over losses of $(0.40) per share from the same
Benzinga Newsdesk
PRO
Carlsmed Q3 EPS $(0.45) Misses $(0.40) Estimate, Sales $21.554M Beat $19.154M Estimate
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.40) by 12.5 percent. This is a 12.5 percent decrease over losses of $(0.40) per share from the
Benzinga Newsdesk
PRO
Carlsmed Raises FY2026 Sales Guidance from $74.000M-$78.000M to $78.000M-$80.000M vs $76.944M Est
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $74.000 million-$78.000 million to $78.000 million-$80.000 million vs $76.944 million estimate.
Benzinga Newsdesk
PRO
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ:CARL) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
Benzinga Newsdesk
PRO
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been
Benzinga Newsdesk